Toxicological Sciences

Dr. Edward V. Ohanian Receives Walter F. Snyder Environmental Health Award from NSF and the National Environmental Health Association (NEHA)

Retrieved on: 
Thursday, August 3, 2023
Manufacturing, Health, General Health, Environmental Health, Utilities, Research, Oil, Gas, Environment, Energy, Science, Chemicals, Plastics, Occupational safety and health, Society, Drinking water, CIH, Public, Toxicokinetics, Safe Drinking Water Act, Associate, Drinking, Risk, Risk assessment, OST, George Washington, National Center for Healthy Housing, United States Environmental Protection Agency, Safe, NSF, Toxicology, NCEA, Toxicological Sciences, EPA, Human and Ecological Risk Assessment, Conference, Book, Arnold, Clean Water Act, Safety, Environmental impact assessment, US EPA, Environmental health, OW, ORD, Multimedia, Public health, Biophysical environment, WHO, Regulation, Letter, Milken Institute School of Public Health, The Woman Who Drinks, Doctor of Public Health, SOT, State, Walter, World Health Organization, Management, Medical device, Nursing

NSF , the leading global public health and safety organization, and the National Environmental Health Association (NEHA), which represents more than 6,000 members of the environmental health workforce, announced today that Dr. Edward V. Ohanian is the 2023 recipient of the Walter F. Snyder Environmental Health Award.

Key Points: 
  • NSF , the leading global public health and safety organization, and the National Environmental Health Association (NEHA), which represents more than 6,000 members of the environmental health workforce, announced today that Dr. Edward V. Ohanian is the 2023 recipient of the Walter F. Snyder Environmental Health Award.
  • Founded in 1971, the Snyder Award honors Walter F. Snyder, co-founder and first executive director of NSF, and individuals who, like him, pioneer environmental and public health through their careers.
  • Snyder Award nominations are open to the public, with recipients selected by a juror panel of environmental health leaders.
  • For more information about the Walter F. Snyder Award or to nominate a colleague for next year’s award, visit NSF’s website .

DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine

Retrieved on: 
Thursday, June 16, 2022
Technology, Consulting, Other Technology, Professional Services, Software, Other Health, Biotechnology, Pharmaceutical, Health, Data Management, Solution, Population, FDA, CGRP, LinkedIn, Safety, Technology, Economics, Simulations Plus, Migraine, Company, U.S. Securities and Exchange Commission, Pharmacokinetics, Risk, Biotechnology, Mission statement, Research, Private Securities Litigation Reform Act, Biophysical environment, Liver injury, Drug discovery, Oxford University Press, Volunteering, Toxicological Sciences, Nasdaq, Software, Patient, Hepatotoxicity, ESG, SLP, Toxicology, Pharmaceutical industry

The results help explain the differentiation in liver safety between small molecule calcitonin gene-related peptide (CGRP) receptor antagonists designed to treat migraine, a debilitating and important unmet medical need.

Key Points: 
  • The results help explain the differentiation in liver safety between small molecule calcitonin gene-related peptide (CGRP) receptor antagonists designed to treat migraine, a debilitating and important unmet medical need.
  • DILIsym predicted the safety of next-generation molecules, which have now proven their safety in the clinic.
  • Rimegepant, for example, was approved for the preventative treatment of migraine by the FDA in the Spring of 2021.
  • Jeffrey Woodhead , Principal Scientist from Simulations Plus, is the first author of the publication entitled Comparing the Liver Safety Profiles of 4 Next-Generation CGRP Receptor Antagonists to the Hepatotoxic CGRP Inhibitor Telcagepant Using Quantitative Systems Toxicology Modeling.

ScitoVation Nabs Leslie Recio, PhD DABT, as Chief Scientific Officer

Retrieved on: 
Thursday, April 28, 2022
ILS, University, CEO, Pacific Economic Cooperation Council, Genetic, Toxicological Sciences, DABT, Leadership, Method, European Menopause and Andropause Society, ISCB Senior Scientist Award, Organization, Environmental Mutagenesis and Genomics Society, Society, Partnership, OECD, Principal, GEMS, Biomarker, Animal, Genetics, SOT, Editing, Research, Hepatocyte, NAM, Doctor of Philosophy, MIT, Council, Risk, Black Panther Party, Winston-Salem, North Carolina Chapter, National Toxicology Program, Mutagen, American Board of Commissioners for Foreign Missions, NTP, Society of Toxicology, Medical device, Management, Mutagenesis, Microbiology, Toxicology

DURHAM, N.C., April 28, 2022 /PRNewswire-PRWeb/ -- ScitoVation is pleased to announce Leslie Recio, PhD, DABT, as the new Chief Scientific Officer. Dr. Recio was the Chief Scientific Officer and Director of the Genetic and Molecular Toxicology group at ILS. Dr. Recio will help lead the team of Senior Scientists, drive priorities in New Approach Methods and help secure new business ventures.

Key Points: 
  • Dr. Recio joins ScitoVation as the Chief Scientific Officer to drive priorities in New Approach Methods and help secure new business ventures.
  • DURHAM, N.C., April 28, 2022 /PRNewswire-PRWeb/ -- ScitoVation is pleased to announce Leslie Recio, PhD, DABT, as the new Chief Scientific Officer.
  • Dr. Recio was the Chief Scientific Officer and Director of the Genetic and Molecular Toxicology group at ILS.
  • Dr. Recio has over 30 years of experience in toxicology research in the areas of mutagenesis, toxicogenomics, and regulatory genotoxicity assessments.

Elevar Therapeutics Announces New Appointments to Strengthen Its Senior Leadership Team

Retrieved on: 
Monday, September 27, 2021
Biochemistry, Mike Hopkins (basketball), Therapy, University of Illinois at Chicago College of Dentistry, Sun Pharma, Pharmacokinetics, University, School, NDA, Toxicological Sciences, Doctor of Philosophy, Patient, Microbiology, Data management, Toxicology, Royal commission, Stomach, Ovarian cancer, Pharmacology, Paclitaxel, Leadership, Biopharmaceutical, Johns Hopkins University, Public health, Jiangsu Hengrui Medicine, European Commission, Drug development, VP, SALT, Orphan drug, DMPK, Academy, Pharmaceutical industry

These key strategic appointments will significantly strengthen our organization's drug development capabilities and clinical expertise, as we continue to build Elevar into a fully integrated biopharmaceutical company," said Maureen G. Conlan, M.D., F.A.C.P., Chief Medical Officer of Elevar Therapeutics.

Key Points: 
  • These key strategic appointments will significantly strengthen our organization's drug development capabilities and clinical expertise, as we continue to build Elevar into a fully integrated biopharmaceutical company," said Maureen G. Conlan, M.D., F.A.C.P., Chief Medical Officer of Elevar Therapeutics.
  • Robert "Bob" Faulkner, Ph.D., F.C.P., F.C.C.P.joins Elevar as VP of DMPK/clinical pharmacology from Sun Pharmaceutical Industries Ltd. (Sun Pharma) where he served as senior director of clinical pharmacology & biopharmaceutics.
  • In his new role, Bob's responsibilities will span all Elevar development programs, as well as exploratory studies to support evaluation of potential pipeline expansions.
  • joins Elevar as VP of non-clinical development from Voisin Consulting Life Sciences where he served as senior director, nonclinical and early clinical development.